- Company has signed partnership with Sanmina Corp., a global contract electronics manufacturer, that sets the foundation for the commercialization and launch of products
- SOLY’s Rapid Acoustic Pulse device, designed to use shockwaves to accelerate tattoo removal, received institutional review board approval as a non-significant risk device
- Higher energy versions of acoustic pulse devices are in early stages of development for potential treatment of cellulite and other indications
Soliton Inc. (NASDAQ: SOLY) has reached an agreement with Sanmina, one of the world’s largest medical device manufacturers, to provide the design and testing to advance Soliton’s Rapid Acoustic Pulse (“RAP”) device for use in future clinical trials. The successful execution of this strategy is expected to lay the foundation for a commercial launch of Soliton’s products (http://nnw.fm/4tZeA).
RAP is a device that uses proprietary platform technology licensed from the MD Anderson Cancer Center. The device is designed to use rapid pulses of acoustic shockwaves together with existing lasers to accelerate the removal of unwanted tattoos.
Soliton also announced that its RAP device received institutional review board approval as a non-significant risk device. The FDA-registered board has been designated to review and monitor biomedical research involving human subjects. Subsequently, Soliton conducted several human clinical trials to study the use of the RAP device to accelerate tattoo fading and also initiated a proof-of-concept trial in humans for the reduction of cellulite (http://nnw.fm/X8P9D).
“Working with Sanmina in this commercialization phase not only provides us with world-class quality and documentation, but we also believe it will make for a smoother transition to manufacturing, which we expect to begin here in the US later this year,” Soliton CEO Dr. Chris Capelli stated in a news release.
Based in Houston, Texas, Soliton is a medical device company with a proprietary platform technology licensed from the University of Texas on behalf of MD Anderson.
Also in the early stages of development is a device that uses higher energy versions of acoustic pulse devices for potential stand-alone treatment of cellulite and other indications. Both products by Soliton are investigational and not yet available for sale in the United States.
For more information, visit the company’s website at www.Soliton.com
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
